ArticleJournal of medical cases2025
Angiotensin II to Treat Intraoperative Vasoplegic Shock in an Infant.
Article in Journal of medical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Angiotensin II as a Vasoactive Agent to Treat Distributive Shock With a Focus on Preliminary Data in Pediatric-Aged Patients.Paediatric anaesthesia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoplegic shock is defined by a pathological reduction in systemic vascular resistance, leading to hypotension despite normal or elevated cardiac output. A key therapeutic challenge lies in the profound and often refractory nature of the hypotension, which may not respond to conventional fluid resuscitation or adrenergic vasopressors. In this report, we describe the intraoperative use of a novel vasoactive agent, angiotensin II, for the treatment of vasoplegic shock during bilateral nephrectomy in an infant. We review current therapeutic options for vasoplegic shock, summarize existing pediatric reports involving angiotensin II, and discuss its emerging role in the management of this difficult-to-treat condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.